MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
RDNT stock logo

RDNT

RadNet, Inc.

$56.18
2.02
 (3.73%)
Exchange:  NASDAQ
Market Cap:  4.418B
Shares Outstanding:  20.016M
Delayed data
Calculate RDNT Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Diagnostics & Research
   
CEO:  Howard G. Berger
Full Time Employees:  11000
Address: 
1508, 1510 and 1516 Cotner Avenue
Los Angeles
CA
90025-3303
US
Website:  https://www.radnet.com
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/11 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,616,6301,829,6642,040,210
Gross Profit221,391249,11590,804
EBITDA292,786262,549242,931
Operating Income98,697104,62190,804
Net Income3,0442,793-18,652

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,690,4733,286,6903,758,563
Total Liabilities1,877,1142,153,2802,402,677
Total Stockholders Equity630,695902,3081,089,890
Total Debt1,491,1201,728,8631,858,854
Cash and Cash Equivalents342,570740,020767,215

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow220,863233,023298,820
Capital Expenditure-176,600-231,731-213,251
Free Cash Flow44,2631,29285,569
Net Income3,04438,83646,771
Net Change in Cash214,736397,45027,195

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2028Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)3,041,708.500Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)3,063,836Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)3,052,772.250Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)517,165.083Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)520,927.301Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)519,046.192Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)86,725.503Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)96,361.837Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)89,588Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)0Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)0Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)0Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.220Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.280Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)1.150Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)4Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
1.83B  ?P/S
 (TTM)
: 
1.99
?Net Income
 (TTM)
: 
2.793M  ?P/E
 (TTM)
: 
-295.05
?Enterprise Value
 (TTM)
: 
5.752B  ?EV/FCF
 (TTM)
: 
-38.67
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.01  ?ROIC
 (TTM)
: 
0.02
?Net Debt
 (TTM)
: 
988.843M  ?Debt/Equity
 (TTM)
: 
1.79
?P/B
 (TTM)
: 
3.88  ?Current Ratio
 (TTM)
: 
1.17

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
108.04Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates RDNT intrinsic value between $0.24 – $0.25 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about RDNT valuation

Is RadNet, Inc. (RDNT) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for RadNet, Inc. (RDNT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is RDNT a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether RDNT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is RDNT’s P/E ratio?

You can see RDNT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for RDNT?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is RDNT a good long-term investment?

Whether RDNT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

RDNT

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

3.73
MARKETSnap

Trading Metrics:

Open: 54.28   Previous Close: 54.16
Day Low: 53.64   Day High: 56.31
Year Low: 50.76   Year High: 85.84
Price Avg 50: 55.84   Price Avg 200: 68.91
Volume: 637087   Average Volume: 837315

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Do Options Traders Know Something About RadNet Stock We Don't?
02-06-2026 09:50
Do Options Traders Know Something About RadNet Stock We Don't?
RadNet to Host Men's Health Webinar on June 13, 2026
28-05-2026 06:00
RadNet to Host Men's Health Webinar on June 13, 2026
RadNet Q1 Earnings Call Highlights
11-05-2026 13:11
RadNet Q1 Earnings Call Highlights
24,848 Shares in RadNet, Inc. $RDNT Purchased by Campbell Newman Asset Management Inc.
17-04-2026 03:38
24,848 Shares in RadNet, Inc. $RDNT Purchased by Campbell Newman Asset Management Inc.
GE HealthCare expands mammography collaboration with RadNet's DeepHealth subsidiary to extend global access to DeepHealth's AI-powered breast cancer screening solutions
16-04-2026 16:05
GE HealthCare expands mammography collaboration with RadNet's DeepHealth subsidiary to extend global access to DeepHealth's AI-powered breast cancer screening solutions
RadNet, Inc. (RDNT) GLEAMER SAS - M&A Call Transcript
05-03-2026 16:46
RadNet, Inc. (RDNT) GLEAMER SAS - M&A Call Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read